Market Closed -
Nasdaq
21:00:00 31/05/2024 BST
5-day change
1st Jan Change
3
USD
-1.32%
-1.64%
-27.54%
Relmada Therapeutics, Inc. Announces Resignation of Thomas Wessel as Executive Vice President and Head of Research and Development
January 05, 2021 at 09:02 pm
On December 31, 2020, Dr. Thomas Wessel, who served as Relmada's Executive Vice President and Head of Research and Development, departed the company.
Transcript : Relmada Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024
05-08
Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-08
CI
Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024
03-19
Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
03-19
CI
Relmada Says Chief Medical Officer Leaving; Names Senior Clinical Development Advisor
01-04
MT
Relmada Therapeutics, Inc. Announces Resignation of Cedric O?Gorman as Chief Medical Officer
01-03
CI
Transcript : Relmada Therapeutics, Inc., Q3 2023 Earnings Call, Nov 08, 2023
11-08
Relmada Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-08
CI
Relmada Therapeutics Reports Positive Preclinical Data on its Psilocybin Program to Treat Liver Disease
11/10/23
MT
Relmada Therapeutics to Present New Preclinical Data on Its Psilocybin Program At AASLD the Liver Meeting 2023
11/10/23
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from S&P Global BMI Index
18/09/23
CI
Relmada Therapeutics, Inc. Announces Eric Schmidt to Resign from the Board, Chairman of the Audit Committee of the Board and as A Member of the Corporate Governance and Nominating Committee of the Board
06/09/23
CI
Relmada Therapeutics Doses First Person in Phase 3 Trial of REL-1017 for Major Depressive Disorder
23/08/23
MT
Relmada Therapeutics, Inc. Announces Dosing of First Patient in Relight, a Phase 3 Trial of Relight, a Phase 3 Trial of Relight for the Adjunctive Treatment of Major Depressive Disorder
23/08/23
CI
Transcript : Relmada Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023
08/08/23
Relmada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
08/08/23
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 3000 Index
23/06/23
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 3000E Value Index
23/06/23
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell Small Cap Completeness Index
23/06/23
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 2500 Index
23/06/23
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 2000 Index
23/06/23
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 2000 Value Index
23/06/23
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell Microcap Growth Index
23/06/23
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 3000E Growth Index
23/06/23
CI
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell 3000 Growth Index
23/06/23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Companyâs lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
More about the company
Average target price
10.88
USD
Spread / Average Target
+262.50%
Consensus
1st Jan change
Capi.
-27.54% 90.52M +11.91% 118B +11.60% 106B -4.68% 24.28B -0.82% 21.96B -10.12% 18.16B -42.12% 16.37B -17.47% 15.56B +2.77% 13.63B +34.58% 12.27B
Bio Therapeutic Drugs
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
RELMADA THERAPEUTICS, INC. 
